Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Truist Securities Initiates Coverage On Janux Therapeutics with Buy Rating, Announces Price Target of $100

Author: Benzinga Newsdesk | September 10, 2025 08:19am
Truist Securities analyst Asthika Goonewardene initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Buy rating and announces Price Target of $100.

Posted In: JANX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist